Anticoagulation therapy in elderly patients with atrial fibrillation

Abstract

In this countrywide atrial fibrillation registry, 61% of elderly patients received VKA, a decision driven mainly by stroke risk. VKA use was not higher in patients with low bleeding risk.

Real‐World Clinical Characteristics and Treatment Patterns of Individuals Aged 80 and Older with Nonvalvular Atrial Fibrillation: Results from the ReAl‐life Multicenter Survey Evaluating Stroke Study

“…21 In a nationwide registry in Greece, 61% of elderly adults with AF received VKAs, with many receiving antiplatelet therapy. 22 It was demonstrated in a Japanese community-based cohort of elderly adults with AF that OAC use decreases gradually with age, with only 41.3% of individuals aged 85 and older taking OACs. 23 Data on clinical characteristics and management of AF in elderly adults are much more limited in Turkey.…”

Characteristics of warfarin under-prescription in older adults with atrial fibrillation

“…When compared to antiplatelet therapy, anticoagulation decreases the risk of stroke with similar bleeding risk [19] . Despite the proven benefit and low risk of bleeding with falls, anticoagulants remain underutilized in the old adults (≥75 years old) [20] , [21] , [22] , [23] , [24] , [25] . Despite the advent of direct oral anticoagulants (DOAC), warfarin is still prescribed more frequently (i.e.…”